SHINE expects to stay on track with prototype, production facility
JANESVILLE -- SHINE Medical Technologies expects to stay on track with construction of its new facilities along Highway 51, SHINE CEO Greg Piefer said to a small group of employees and community members Wednesday.
SHINE plans to be in full commercial production by early to mid 2020, Piefer said. This is consistent with a timeline announced at the August ground-breaking of its Building One prototype facility.
Piefer spoke at a community update event at Holiday Inn Express.
Ground was broken for the 11,500-square-foot Building One on Aug. 3, and it is expected to be operational in 2018, Piefer said. The company plans to obtain an occupancy permit in January.
The company plans to use the prototype facility to show potential investors that its nuclear accelerator technology works.
The facility will operate as a miniature lab, allowing SHINE to test, improve and demonstrate its intended moly-99 production process using a particle accelerator and low-enriched uranium.
The prototype project, not part of SHINE's original plans, was part of a $1.5 million expansion of the city's $9 million tax incentive package for SHINE's Janesville project. The Janesville City Council approved the extra $1.5 million in June.
Ground-breaking on a full-scale production facility next door to the prototype is planned for mid-2018 at the earliest, Piefer said.
Piefer in September told the city council construction of the full-scale facility would begin in the second quarter of 2018 and be completed by late 2019.
SHINE has selected Ohio-based Baker Concrete Construction as its main contractor for its full-scale production facility, Piefer said. SHINE plans to hire as many local contractors as possible to supplement Baker Concrete, he said.
The production facility will produce molybdenum-99, an isotope used to light up bone and soft tissue in medical tests, including bone scans, cancer scans and heart tests.
No production will be done at Building One, Piefer said. It will be used to test and demonstrate the company's particle accelerator technology.
Building One and the production facility will be across Highway 51 from the Southern Wisconsin Regional Airport, Piefer said.
Close proximity to the airport was intentional, Piefer said. Medical isotopes decay quickly and need to be shipped as soon as possible.
About $120 million of molybdenum-99 has been sold by SHINE in advance of production, Piefer said.
SHINE has signed contracts to provide moly-99 for GE Healthcare, Lantheus Medical Imaging and HTA in China.
The company employs about 60 people in Janesville and hopes to add 10 or 11 more in the coming months, Piefer said.
Since moving into its corporate offices in downtown Janesville late last year, Piefer said, the company has been active in the community. He mentioned working with local nonprofits, including ECHO and the Salvation Army.